Boehringer Ingelheim and Eli Lilly’s alliance that was chalked out in January 2011 will launch its first product in India after its collaboration. Linagliptin, an oral drug for Type 2 diabetes in adults will soon be made available at chemist outlets. The drug is priced at INR 42.70 per dose. The drug is exceptional for its “renal-friendly” nature and ability to control possible weight gain and low-sugar attack on patients.
The products are being priced in accordance to Indian market affordability and the companies will be sharing the costs, profits and revenues.
Source: Business Line